Depomed (DEPO): September Rx Data Increases Confidence - Janney

October 14, 2016 9:41 AM EDT
Get Alerts DEPO Hot Sheet
Price: $23.12 -0.39%

Rating Summary:
    10 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade DEPO Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Janney Montgomery Scott analyst, Ken Trbovich, reiterated his Buy rating on shares of DepoMed Inc (NASDAQ: DEPO) after Horizon (NASDAQ: HZNP) and Insys (NASDAQ: INSY) both prereleasesd negative 3Q16 topline guidance. The analyst does not believe the weakness will impact DEPO.

In September, DEPO's Rx performance exceeded his forecast on 4/6 products and on 3/6 products for the quarter as a whole. Those that fell short of expectations were within 1%-3% of the forecast. Therefore, while his is modestly cutting "Street' high estimates, the strength of prescription demand for DEPO's products in September and throughout the quarter, give us him confidence DEPO is on track to meet, or beat, current consensus estimates.

No change to the price target of $31.

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $24.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change

Related Entities

Janney Montgomery Scott

Add Your Comment